Published in World J Gastroenterol on January 28, 2016
A proposed predictive model for advanced fibrosis in patients with chronic hepatitis B and its validation. Medicine (Baltimore) (2016) 0.75
Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. Ann Transl Med (2017) 0.75
Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (2009) 22.53
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology (1996) 12.47
Mechanisms of hepatic fibrogenesis. Gastroenterology (2008) 11.98
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18
Liver biopsy. N Engl J Med (2001) 9.91
Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology (2005) 9.44
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol (2002) 8.21
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92
Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology (2004) 6.14
Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology (2005) 5.93
Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet (2001) 5.82
Liver fibrosis -- from bench to bedside. J Hepatol (2003) 5.80
Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology (2008) 5.77
FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology (2007) 5.53
Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol (2003) 5.17
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology (2009) 4.82
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology (2006) 4.60
Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology (2008) 4.53
EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol (2013) 4.46
Evaluation of liver fibrosis: a concise review. Am J Gastroenterol (2004) 4.37
Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med (2010) 4.14
Noninvasive assessment of liver fibrosis. Hepatology (2010) 3.86
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med (2013) 3.39
Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology (2011) 3.38
Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem (2005) 2.99
Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat (2007) 2.87
Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology (2008) 2.76
Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol (2007) 2.75
Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango? Gut (2010) 2.70
Apoptosis: the nexus of liver injury and fibrosis. Hepatology (2004) 2.70
Sources of variability in histological scoring of chronic viral hepatitis. Hepatology (2005) 2.64
Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol (2005) 2.64
Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol (2006) 2.61
Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology (2011) 2.49
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology (2009) 2.45
Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology (2004) 2.41
A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology (2005) 2.38
Diagnosis and quantitation of fibrosis. Gastroenterology (2008) 2.20
Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol (2003) 2.19
Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology (2008) 2.02
An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol (2011) 1.98
Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatology (2012) 1.94
Liver biopsy:complications and risk factors. World J Gastroenterol (1999) 1.91
Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study. Hepatology (2007) 1.81
Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med (2003) 1.80
A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol (2011) 1.79
The role of liver biopsy in chronic hepatitis C. Hepatology (2002) 1.77
Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet (1993) 1.69
Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients. Am J Med (2007) 1.66
Non-invasive markers for hepatic fibrosis. BMC Gastroenterol (2011) 1.65
Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol (2006) 1.63
Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol (2004) 1.60
Hepatitis C virus infection induces apoptosis through a Bax-triggered, mitochondrion-mediated, caspase 3-dependent pathway. J Virol (2008) 1.60
Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology (2002) 1.51
Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol (2007) 1.50
Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol (2004) 1.49
Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology (2003) 1.46
Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. Gut (2008) 1.43
Expanding the applicability of noninvasive fibrosis markers in HIV/HCV co-infected patients. Hepatology (2007) 1.42
HCV induces oxidative and ER stress, and sensitizes infected cells to apoptosis in SCID/Alb-uPA mice. PLoS Pathog (2009) 1.40
Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med (2004) 1.39
Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Aliment Pharmacol Ther (2007) 1.38
Hepatitis C virus infection and apoptosis. World J Gastroenterol (2007) 1.36
Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat (2011) 1.36
Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol (2011) 1.29
Apoptosis in hepatitis C virus infection. Cell Death Differ (2003) 1.28
Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest. Dig Dis Sci (1994) 1.26
Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol (2005) 1.25
Mechanisms of Disease: HCV-induced liver injury. Nat Clin Pract Gastroenterol Hepatol (2007) 1.22
Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol (2008) 1.21
Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels. Hepatology (2000) 1.21
Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology (2001) 1.19
Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol (2010) 1.19
Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol (2005) 1.19
Transforming growth factor-beta 1 in chronic hepatitis C. J Viral Hepat (1997) 1.18
Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol (2009) 1.18
Non-invasive assessment of liver fibrosis: are we ready? Lancet (2010) 1.17
Chronic hepatitis C in children: the pathological and clinical spectrum. Gastroenterology (1998) 1.17
Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatology (1998) 1.14
Concordance in a world without a gold standard: a new non-invasive methodology for improving accuracy of fibrosis markers. PLoS One (2008) 1.13
Apoptosis and liver disease. Am J Med (2000) 1.13
Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy? Gastroenterology (2005) 1.13
Apoptosis in hepatitis C. J Viral Hepat (2003) 1.13
Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. J Pediatr Gastroenterol Nutr (2010) 1.13
The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum. Hepatology (2005) 1.10
Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur J Gastroenterol Hepatol (2000) 1.10
Chronic hepatitis C virus infection in children. J Pediatr Gastroenterol Nutr (2010) 1.09
Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol (2003) 1.09
Comparison of sulphated glycosaminoglycan and hyaluronate synthesis and secretion in cultured hepatocytes, fat storing cells, and Kupffer cells. J Clin Chem Clin Biochem (1989) 1.08
Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. J Viral Hepat (2006) 1.07
Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med (2007) 1.07
Diagnostic value of serum markers of connective tissue turnover for predicting histological staging and grading in patients with chronic hepatitis C. J Gastroenterol (2001) 1.06
Biomarkers of liver cell death. J Hepatol (2014) 1.06
Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Int (2006) 1.06
Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. World J Gastroenterol (2014) 1.05
Pathology of chronic hepatitis C in children. Child Liver Study Group of Japan. Hepatology (1997) 1.05
Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats. Fibrogenesis Tissue Repair (2010) 1.05